Global Biological API Drug Manufacturing Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
- SKU ID : GIR-GIR1911270004 14818682
- |
- Publishing Date: 30-Dec-2019
- |
- Region: Global
- |
- No. of pages: 132
Description
The worldwide market for Biological API Drug Manufacturing is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new study.
This report focuses on the Biological API Drug Manufacturing in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Lonza
AbbVie
DSM
Boehringer Ingelheim BioXcellence
Cytovance Biologics
Celltrion
CEPiA Sanofi
Fujifilm Diosynth Biotechnologies
Samsung BioLogics
Baxter
Wuxi Biologics
GSK
Vetter
Pfizer CentreOne
Sandoz
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
In-House manufacturing
Contract manufacturing
API contract manufacturing dominates the global biological API drug manufacturing market.
Monoclonal Antibody (mAb) Therapies
Vaccines
Insulin Therapies
Interferon Therapies
Other
Chapter 1, to describe Biological API Drug Manufacturing product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Biological API Drug Manufacturing, with price, sales, revenue and global market share of Biological API Drug Manufacturing in 2017 and 2018.
Chapter 3, the Biological API Drug Manufacturing competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biological API Drug Manufacturing breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Biological API Drug Manufacturing market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Biological API Drug Manufacturing sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Scope of the Report:
The worldwide market for Biological API Drug Manufacturing is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new study.
This report focuses on the Biological API Drug Manufacturing in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Lonza
AbbVie
DSM
Boehringer Ingelheim BioXcellence
Cytovance Biologics
Celltrion
CEPiA Sanofi
Fujifilm Diosynth Biotechnologies
Samsung BioLogics
Baxter
Wuxi Biologics
GSK
Vetter
Pfizer CentreOne
Sandoz
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
In-House manufacturing
Contract manufacturing
API contract manufacturing dominates the global biological API drug manufacturing market.
Market Segment by Application
s, can be divided into
Monoclonal Antibody (mAb) Therapies
Vaccines
Insulin Therapies
Interferon Therapies
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biological API Drug Manufacturing product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Biological API Drug Manufacturing, with price, sales, revenue and global market share of Biological API Drug Manufacturing in 2017 and 2018.
Chapter 3, the Biological API Drug Manufacturing competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biological API Drug Manufacturing breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Biological API Drug Manufacturing market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Biological API Drug Manufacturing sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
